There are now more than 520 FDA-cleared AI algorithms and the majority are for radiology and cardiology, raising the question of who is liable if the AI gets something wrong.

A therapeutic oncology company has been cleared to market a cancer treatment that that turns a tumor’s own biology into a self-signaling target for radiation therapy.

Brent Savoie, MD, JD, vice chair for radiology informatics, section chief of cardiovascular imaging, Vanderbilt University, explains who will get sued when there is a misdiagnosis due to artificial intelligence (AI).

The FDA has cleared U.K.-based Adaptix to market a 3D X-ray system that, according to the company, images hands, feet and elbows “at a fraction of the radiation dose and per-study cost of traditional CT.”

Remember the radiologist who drove himself and his family over a rocky California cliff in an alleged—and fortunately failed—suicide-murder attempt? He’s out of the hospital and in jail.

The executive branch of the European Union has launched a major project to aggregate cancer imaging data from across the continent so it can be readily tapped by healthcare providers, medical schools and industry innovators.

The FDA has declined to accelerate approval of Eli Lilly’s highly anticipated Alzheimer’s drug, but the reason for the rejection may presage a forthcoming thumbs-up.

The American College of Radiology has worked out a way to protect patients from surprise medical bills for out-of-network services while modifying third-party arbitration so it sensibly serves providers and payers alike.